Sridevi Rajeeve, MD
Myeloma Specialist & Cellular Therapist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
Conditions I Treat
- Multiple myeloma and other plasma-cell diseases
- Smoldering multiple myeloma (SMM)
- Monoclonal gammopathy of undetermined significance (MGUS)
My Specialties
- Cellular therapy
- Chemotherapy
- Immunotherapy
About Me
- Assistant Attending Physician
I am a hematologist-oncologist and physician-researcher who specializes in treating plasma cell disorders and has additional expertise in cellular therapies. Plasma cell disorders include a wide range of cancerous and non-cancerous conditions, including but not limited to:
- Multiple myeloma (the second most common blood cancer)
- Smoldering myeloma
- Monoclonal gammopathy of undetermined significance (MGUS)
- Plasmacytomas
- Plasma cell leukemia
- Waldenstrom’s macroglobulinemia
- Light chain (AL) amyloidosis, and
- POEMS syndrome
Read more
Together with my colleagues at Memorial Sloan Kettering Cancer Center (MSK), I offer a variety of treatment options. This includes standard-of-care medications, like chemotherapy, immunotherapy, and cellular therapies, and the latest cutting-edge clinical trials available at MSK — one of the world’s oldest and best centers for cancer care.
A cancer diagnosis abruptly transforms the lives of both patients and their loved ones. Each patient, their support systems, and environment are unique; my goal is to holistically think about all of these elements and, together with my patients, decide what treatment approach is best, based on their individual needs, wishes, and goals. I value communication and place high importance on patients and their caregivers understanding the disease process, treatment options, benefits, risks, and alternatives.
My research interests include:
- Studying new drugs for plasma cell disorders
- Identifying patients who either have a high risk for disease progression (cancer continues to grow) or are not responding to standard therapies
- Developing cellular therapies and managing their side effects
- Digital health
- Improving healthcare delivery, and
- Global health initiatives
The field of multiple myeloma has significantly advanced, thanks to newer immunotherapies and cellular therapies that are helping patients to live longer and better. I am involved in a number of clinical trials and projects evaluating novel therapeutic approaches for plasma cell disorders. I currently practice in both New York City and New Jersey, with the goal of providing MSK’s expertise and facilities to all those in need.
Watching my brilliant scientist grandfather succumb to an aggressive form of brain cancer during my formative teenage years laid the foundation for me to pursue oncology as my calling long before medical school. I am grateful to be able to live that dream and am deeply committed to ensuring every patient feels comfortable in the care that they are receiving at MSK.
Outside the clinic and the lab, I am an avid bibliophile and enjoy adventure sports like skiing and traveling to places of historical significance.
A myeloma specialist is a doctor with special training in diagnosing and treating myeloma.
A cellular therapy specialist is a doctor with special training in using cell therapies to treat health conditions such as cancer. Therapies can include chimeric antigen receptor (CAR) T cell therapy.
Conditions I Treat
- Multiple myeloma and other plasma-cell diseases
- Smoldering multiple myeloma (SMM)
- Monoclonal gammopathy of undetermined significance (MGUS)
- Solitary or extramedullary plasmacytoma
- Lymphoplasmacytic lymphoma (Waldenstrom macroglobulinemia)
- Light chain (AL) amyloidosis
My Specialties
- Cellular therapy
- Chemotherapy
- Immunotherapy
- Clinical trials
Education
- MD, Mahatma Gandhi University, Kerala, India
Residencies
- Internal Medicine - Icahn School of Medicine at Mount Sinai/Morningside & West
Awards and Honors
- Domestic Scholar Award, AIDS malignancy consortium (AMC, 2022-2024)
- Young Investigator Award (YIA), American Society of Clinical Oncology (ASCO, 2022-2023)
- AACR/ASCO Methods in Cancer Clinical Research Workshop, Vail, Colorado (2022)
- Patient Education Ambassadorship, Global Resource for Advancing Cancer Education (GRACE, 2022)
- Excellence in Fellow Mentorship Award, Icahn School of Medicine at Mount Sinai/Morningside-West (2022)
- Hematology Opportunities for Next Generation of Research Scientists Award (HONORS), American Society of Hematology (ASH, 2019)
- Tristate Critical Care Simulation Wars Championship, Department of Pulmonary & Critical Care Medicine, Icahn School of Medicine at Mount Sinai/Morningside-West (2018)
- National Best Paper Presentation, ‘Illuminati’ National Research Symposium, Pune, India (2015)
- Valedictorian/Best Outgoing Student Award & Gold Medalist, Mahatma Gandhi University/MOSC Medical College, Kerala, India (2015)
- Dr. Valsa Memorial Award in Preventive and Social Medicine, Mahatma Gandhi University/MOSC Medical College, Kerala, India (2014)
- 3rd Prize, Neurology Quiz, Kerala Association of Neurologists (2013)
Fellowships
- Hematology & Medical Oncology - Icahn School of Medicine at Mount Sinai
Board Certifications
- Hematology
- Medical Oncology
- Internal Medicine
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
Contact and Location
Dr. Rajeeve sees patients at two locations.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Rajeeve
- A Phase 1/2 Study of AZD0305 to Treat Multiple Myeloma
- A Phase 1b Study of CLN-619 in People With Multiple Myeloma
- A Phase II Study of JNJ-68284528 CAR T-Cell Therapy to Treat Multiple Myeloma
- Clinical Trials Co-Investigated by Dr. Rajeeve
- A Phase 1 Study of BMS-986453 CAR T Cell Therapy in People With Multiple Myeloma
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Rajeeve’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Sridevi Rajeeve discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].